EP1911447A1 - Eye drop preparation comprising xanthan gum and terpenoid - Google Patents
Eye drop preparation comprising xanthan gum and terpenoid Download PDFInfo
- Publication number
- EP1911447A1 EP1911447A1 EP06781152A EP06781152A EP1911447A1 EP 1911447 A1 EP1911447 A1 EP 1911447A1 EP 06781152 A EP06781152 A EP 06781152A EP 06781152 A EP06781152 A EP 06781152A EP 1911447 A1 EP1911447 A1 EP 1911447A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- xanthan gum
- terpenoid
- menthol
- ophthalmic solution
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Definitions
- the present invention relates to an ophthalmic solution comprising xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content.
- JP-A-2000-273061 discloses an oil-in-water emulsion ophthalmic solution in a plastic container wherein decrease in the terpenoid content is suppressed.
- JP-A-2002-003364 discloses a method of suppressing adsorption of algefacients such as menthol and the like to a container, which comprises adding polyvalent alcohol into a unit-dose (disposable) eyedrop container.
- Lacrimal fluid is known to have pseudoplasticity. That is, the viscosity of lacrimal fluid decreases when a force is applied by blinking, and increases when the force is not applied. Therefore, lacrimal fluid has unique property in that it has low viscosity and becomes thin during blinking to facilitate blinking, but it becomes highly viscose before and after blinking to cover the eye surface for protection.
- xanthan gum is known as a polymer compound showing such pseudoplasticity.
- an ophthalmic composition containing xanthan gum As an ophthalmic composition containing xanthan gum, the following have been reported. For example, an ophthalmic composition containing echothiopate iodide and xanthan gum is disclosed, and xanthan gum has been reported to enhance the treatment effect of echothiopate iodide ( US Patent No. 4136177 ). In addition, an ophthalmic composition containing xanthan gum and a carbonic anhydrase inhibitor has been disclosed, where xanthan gum is used to improve ophthalmic bioavailability of the carbonic anhydrase inhibitor ( JP-T-2001-508035 , JP-T-2002-501017 , JP-T-2002-506461 ).
- xanthan gum For the purpose of improving ophthalmic bioavailability of a drug, xanthan gum is used, and an ophthalmic composition containing a carbonic anhydrase inhibitor, a prostaglandin derivative and xanthan gum has been disclosed ( JP-T-2002-501533 , JP-T-2002-521332 , JP-T-2002-521333 ).
- An ophthalmic composition containing quaternary nitrogen-containing ethoxylated glycoside and xanthan gum has been disclosed for the treatment of dry eye ( JP-T-2001-516713 ).
- an ophthalmic composition containing xanthan gum, which is gelated upon contact with the eye has been disclosed ( JP-T-2002-510654 ).
- US Patent No. 6623751 reports in connection with skin patches that can be adapted to the shape of around the eye, forehead, nose, the mouth and the like, a patch containing a hydrophilic gelling system in an aqueous phase.
- Example 3 of US Patent No. 6623751 reports a patch containing xanthan gum and menthol.
- the present inventors have conducted intensive studies in an attempt to achieve the aforementioned objects and found that addition of xanthan gum to an ophthalmic solution comprising terpenoid can suppress a decrease in the terpenoid content.
- the present inventors conducted further studies based on this finding and accomplished the present invention.
- the present invention relates to
- an ophthalmic solution showing a suppressed decrease in the terpenoid content can be provided by adding xanthan gum.
- a method for suppressing decrease in the content of terpenoid in an ophthalmic solution which comprises adding xanthan gum to an ophthalmic solution containing terpenoid, can be provided.
- the ophthalmic solution of the present invention provides an excellent feel during use due to a viscous feel free of stickiness and a refreshing feel it provides in combination, since it comprises xanthan gum and terpenoid.
- the ophthalmic solution of the present invention encompasses aqueous formulations that can be administered to the eye, for example, aqueous ophthalmic solutions and aqueous ophthalmic suspensions.
- a container to be used for the ophthalmic solution of the present invention is not particularly limited insofar as it is usable for the aqueous formulations, plastic containers are preferable.
- the materials of the plastic containers include polyethylene terephthalate, polyethylene, polypropylene and the like. Polyethylene terephthalate is particularly preferable.
- Xanthan gum to be used for the ophthalmic solution of the present invention generally has an average molecular weight of 100000-50000000, preferably 200000-20000000, and particularly preferably 1000000-10000000.
- ECHO GUM series such as ECHO GUM T, ECHO GUM F and the like that are commercially available from DAINIPPON SUMITOMO PHARMACEUTICAL CO., LTD.
- SAN-ACE series such as SAN-ACE NXG-S and the like commercially available from San-Ei Gen F.F.I.
- KELTROL series such as KELTROL CG, KELTROL CG-T and the like commercially available from Sansho Co., Ltd.; and the like are used, with preference given to ECHO GUM T and KELTROL CG-T.
- the xanthan gum in the ophthalmic solution of the present invention has a concentration of generally 0.01-1.5 w/v%, preferably 0.1-1 w/v%, more preferably 0.15-1 w/v%, particularly preferably 0.2-0.7 w/v%, and especially preferably 0.2-0.6 w/v%, in view of suppression of decrease in the terpenoid content.
- An ophthalmic solution having a xanthan gum concentration of 1.5 w/v% or lower can be produced easily because it has suitable viscosity and allows filtration sterilization under general conditions.
- terpenoids to be used for the ophthalmic solution of the present invention include menthols (1-menthol, d-menthol, dl-menthol and the like); camphors (1-camphor, d-camphor, dl-camphor and the like); monoterpenes (borneol, geraniol, cineol, anethole, limonene, eugenol and like); sesquiterpenes (farnesol, nerolidol and like); diterpenes (phytol, cembrene and like); etc., with preference given to menthol and camphor. These are used in combination of one or more kinds thereof.
- the terpenoid concentration of the ophthalmic solution of the present invention upon preparation is generally 0.0002-0.2 w/v%, preferably 0.001-0.1 w/v%, and particularly preferably 0.002-0.05 w/v%.
- the weight ratio of terpenoid to xanthan gum in the ophthalmic solution of the present invention upon preparation is preferably 1:1000-1:1 and more preferably 1:100-1:10 when the terpenoid concentration is 0.001-0.1 w/v%.
- the weight ratio is preferably 1:350-1:4 and more preferably 1:100-1:10.
- the ophthalmic solution of the present invention can contain various additives as appropriate, such as buffer, isotonicity agent, preservative, solubilizing agent, stabilizer, chelating agent, thickener, pH adjusting agent and the like.
- boric acid or a salt thereof for example, boric acid or a salt thereof (sodium borate, etc.), citric acid or a salt thereof (sodium citrate, etc.), tartaric acid or a salt thereof (sodium tartrate, etc.), gluconic acid or a salt thereof (sodium gluconate, etc.), acetic acid or a salt thereof (sodium acetate, etc.), phosphoric acid or a salt thereof (sodium hydrogenphosphate, sodium dihydrogenphosphate, etc.), various amino acids such as glutamic acid, ⁇ -aminocaproic acid and the like and tris buffer, etc. can be mentioned. They are used in a combination of one or more kinds thereof.
- isotonicity agent for example, sorbitol, glucose, mannitol, glycerol, propylene glycol, sodium chloride, potassium chloride and the like can be mentioned.
- preservative for example, paraoxybenzoates, benzalkonium chloride, benzethonium chloride, benzyl alcohol, sorbic acid or a salt thereof, chlorhexidine or a salt thereof, sodium dehydroacetate, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, chlorobutanol and the like can be mentioned. They are used in a combination of one or more kinds thereof.
- nonionic surfactants such as sorbitan polyoxyethylene fatty acid esters (polysorbate 80 and the like), polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate (polyoxyl stearate 40 and the like) and like, water-soluble polymers such as polyethylene glycol (macrogol 4000 and the like), polyvinylpyrrolidone and the like, propylene glycol, cyclodextrins, and the like can be mentioned.
- nonionic surfactants such as sorbitan polyoxyethylene fatty acid esters (polysorbate 80 and the like), polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate (polyoxyl stearate 40 and the like) and like
- water-soluble polymers such as polyethylene glycol (macrogol 4000 and the like), polyvinylpyrrolidone and the like, propylene glycol, cyclodextrins, and the like can be mentioned.
- the stabilizer for example, disodium edetate, thiosodium sulfate, ascorbic acid, cyclodextrins, condensed phosphoric acid or a salt thereof, sulfite, citric acid or a salt thereof, dibutylhydroxytoluene and the like can be mentioned.
- chelating agent for example, sodium edetate, sodium citrate, condensed phosphoric acid or a salt thereof (condensed sodium phosphate etc.) and the like can be mentioned.
- methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, hyaluronic acid and the like can be mentioned.
- pH adjusting agent for example, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, boric acid or a salt thereof (sodium borate), hydrochloric acid, citric acid or a salt thereof (sodium citrate, sodium dihydrogen citrate etc.), phosphoric acid or a salt thereof (sodium dihydrogen phosphate, potassium dihydrogen phosphate etc.), acetic acid or a salt thereof (sodium acetate, ammonium acetate etc.), tartaric acid or a salt thereof (sodium tartrate etc.) and the like can be mentioned.
- the ophthalmic solution of the present invention is prepared to have pH 3-10 and preferably pH 5-8.
- the ophthalmic solution of the present invention may contain, insofar as the objects of the invention are not impaired, one or more kinds of medicinal components selected from anti-inflammatory agents (allantoin, pranoprofen and the like), decongestants (naphazoline hydrochloride and the like), ocular muscle modulators (neostigmine methylsulfate and the like), astringent agents (zinc sulfate and the like), antihistamine agents (chlorpheniramine maleate and the like), antiallergic agents (sodium cromoglycate and the like), vitamins (panthenol and the like), amino acids, and the like.
- anti-inflammatory agents allantoin, pranoprofen and the like
- decongestants naphazoline hydrochloride and the like
- ocular muscle modulators neostigmine methylsulfate and the like
- astringent agents astringent agents
- antihistamine agents chlorpheni
- amino acid for example, glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, serine, threonine, tyrosine, asparagine, glutamine, lysin, arginine, tryptophan, histidine, cysteine, methionine, aspartic acid, glutamic acid, aminoethylsulfonic acid, and a pharmacologically acceptable salt thereof can be mentioned.
- salt for example, sodium salt, potassium salt, calcium salt and magnesium salt can be mentioned. These are used in a combination of one or more kinds thereof.
- Administration period of the ophthalmic solution of the present invention is not limited.
- the ophthalmic solution can be suitably administered to an administration subject based on the clinically employed amount as a standard.
- the blending ratio of the ophthalmic solution of the present invention and the above-mentioned medicinal components can be suitably selected in consideration of the administration subject, target disease, symptom, combination, and the like.
- the above-mentioned medicinal components may be used in a proportion of 0.0006-5 w/v% relative to the ophthalmic solution of the present invention.
- the ophthalmic solution of the present invention can be used as both ethical drugs and non-prescription drugs. In addition, it can also be used as an ophthalmic solution for contact lenses or a contact lens solution used when wearing contact lenses.
- the ophthalmic solution of the present invention can also be used as an ophthalmic solution for the prophylaxis or improvement of eye fatigue, dryness of eye, blurred vision, ocular itching, conjunctival hyperemia, uncomfortableness by wearing contact lenses, and the like.
- the ophthalmic solution of the present invention can be used as an artificial lacrimal fluid to supplement lacrimal fluid (dryness of the eye) and the like.
- the ophthalmic solution of the present invention when used for an adult, it is preferably administered in an amount of 2-3 drops per installation and 5 or 6 times per day, as an ophthalmic solution containing terpenoid in a proportion of preferably 0.001-0.1 w/v% and particularly preferably 0.002-0.05 w/v%.
- the ophthalmic solution of the present invention exhibits a viscous feel free of stickiness because it contains xanthan gum, which shows pseudoplasticity. Moreover, the ophthalmic solution of the present invention also provides a cool sensation and refreshing feel because it contains terpenoid as an algefacient.
- the present invention provides a method for suppressing decrease in the terpenoid content, which comprises adding xanthan gum to an ophthalmic solution containing terpenoid.
- Sodium chloride was dissolved in purified water at ambient temperature. While mildly stirring the aqueous solution in a homomixer (T.K. Robomix, Tokushu Kika Kogyo Co., Ltd.), xanthan gum (ECHO GUM T: registered trade mark, DAINIPPON SUMITOMO PHARMACEUTICAL CO., LTD.) was gradually added and the mixture was stirred at 15,000 rpm for one hour. 1-Menthol (The Japanese Pharmacopoeia Fourteenth Edition) or dl-camphor (The Japanese Pharmacopoeia Fourteenth Edition) was added to this aqueous solution at room temperature and the mixture was stirred at 8,000 rpm for 10 min to allow dissolution.
- a homomixer T.K. Robomix, Tokushu Kika Kogyo Co., Ltd.
- xanthan gum ECHO GUM T: registered trade mark, DAINIPPON SUMITOMO PHARMACEUTICAL CO., LTD.
- ophthalmic solutions of Comparative Examples 1 and 2 were obtained by an operation in the same manner except addition of xanthan gum.
- Table 1 Components added (g/100 mL) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Comp. Ex. 1 Comp. Ex. 2 Xanthan gum 0.2 0.5 0.7 0.5 - - Sodium chloride 0.9 0.9 0.9 0.9 0.9 1-Menthol 0.01 0.01 0.01 - 0.01 - dl- Camphor - - - 0.01 - 0.01 Purified water e.q. e.q. e.q. e.q. e.q. e.q. e.q. e.q.
- the ophthalmic solutions of Examples 1 to 4 and Comparative Examples 1 and 2 were each filled in a 15 mL polyethylene terephthalate eyedrop container and preserved at 60°C for 2 days.
- the 1-menthol and dl-camphor contents of each sample were measured before and after preservation.
- the quantification method of 1-menthol and dl-camphor is as follows.
- a sample (2 mL) was precisely measured, and precisely 2 mL of chloroform was added thereto.
- the mixture was then vigorously shaken, the chloroform layer was separated and used as a sample solution.
- 0.02 g of 1-menthol standard product was precisely measured, and chloroform was added thereto to precisely 20 mL.
- This solution (2 mL) was precisely measured off, chloroform was added thereto to precisely 20 mL, and the solution was used as an 1-menthol standard solution.
- 0.02 g of dl-camphor standard product was precisely measured, and chloroform was added thereto to precisely 20 mL.
- This solution (2 mL) was precisely measured off, chloroform was added thereto to precisely 20 mL, and the solution was used as a dl-camphor standard solution.
- the sample solution and the standard solution (5 ⁇ L) were tested by gas chromatography. The contents of 1-menthol and dl-camphor were determined from the peak areas thereof.
- the 1-menthol residual ratios increased in Examples 1 to 3 as compared to Comparative Example 1.
- An 1-menthol content decrease-suppressive effect of xanthan gum was observed at respective concentrations of 0.2 to 0.7%.
- the dl-camphor residual rate increased in Example 4 as compared to Comparative Example 2, and a dl-camphor content decrease-suppressive effect of xanthan gum was observed.
- Example 2 and Comparative Example 1 were filled in a 15 mL polypropylene eyedrop container and a 15 mL polyethylene eyedrop container, respectively, and preserved at 60°C for 6 hr.
- the 1-menthol content of each sample before and after the preservation was measured in the same manner as in Experimental Example 1.
- Example 5 As shown in Table 5, the 1-menthol residual rate in Example 2 increased as compared to Comparative Example 1 in both polypropylene eyedrop container and polyethylene eyedrop container. Hence, an 1-menthol content decrease-suppressive effect of xanthan gum was observed.
- Table 5 Menthol content decrease-suppressive effect of xanthan gum in polypropylene or polyethylene eyedrop container (60°C, 6 hr preservation) Xanthan gum content (%) 1-Menthol residual ratio (%) Polypropylene Polyethylene Example 2 0.5 53.0 23.5 Comparative Example 1 0 47.2 15.5
- Example 2 and Comparative Example 1 The ophthalmic solutions of Example 2 and Comparative Example 1 (5 mL each) were filled in 5 mL glass ampoules, a piece of a polyethylene terephthalate container (about 3 g of about 5 mm ⁇ 25 mm piece cut out from the body of container) was immersed therein, and the ampoules were preserved at 60°C for 1 day.
- the 1-menthol content of each sample before and after the preservation was measured in the same manner as in Experimental Example 1.
- one free of immersion of a container piece was treated in the same manner.
- Example 6 the 1-menthol residual rate increased in Example 2 as compared to Comparative Example 1. From this result, it is considered that xanthan gum suppressed adsorption of menthol to the container as one mechanism of the content decrease-suppressive effect.
- Table 6 Menthol content decrease-suppressive effect of xanthan gum in polyethylene terephthalate container (60°C, 1 day preservation) Xanthan gum content (%) 1-Menthol residual rate (%) No container piece With container piece Example 2 0.5 100.4 96.7 Comparative Example 1 0 100.1 91.1
- Formulation examples of the ophthalmic solution comprising xanthan gum and terpenoid of the present invention are shown below.
- An artificial lacrimal fluid of the following formulation was prepared according to a conventional method.
- Potassium 1-aspartate 0.5 g Aminoethylsulfonic acid 0.5 g Sodium chloride 0.5 g Potassium chloride 0.15 g Boric acid 0.3 g Borax q.s.
- Xanthan gum 0.5 g Benzalkonium chloride 0.005 g 1-Menthol 0.005 g Purified water q.s. Total amount 100 ml (pH 7.2)
- a contact lens ophthalmic solution of the following formulation was prepared according to a conventional method.
- Xanthan gum 0.3 g Potassium sorbate 0.1 g 1-Menthol 0.01 g Macrogol 4000 0.3 g Sodium edentate 0.1 g
- a contact lens ophthalmic solution of the following formulation was prepared according to a conventional method.
- Potassium 1-aspartate 0.1 g Sodium chloride 0.3 g Potassium chloride 0.05 g Glucose 0.005 g Boric acid 1 g Borax q.s.
- Sodium citrate 0.5 g Chlorobutanol 0.1 g Xanthan gum 0.3 g Sorbic acid 0.1 g 1-Menthol 0.035 g Macrogol 4000 0.3 g Purified water q.s. Total amount 100 ml (pH 6.5)
- Neostigmine methylsulfate 0.005 g Panthenol 0.1 g Potassium 1-aspartate 1 g Allantoin 0.1 g Chlorpheniramine maleate 0.03 g Sodium chloride 0.45 g Sodium 1-glutamate 0.2 g Polyoxyethylene hydrogenated castor oil 60 0.3 g 1-Menthol 0.008 g Borneol 0.002 g Hydrochloric acid q.s. Benzalkonium chloride 0.005 g Chlorobutanol 0.2 g Xanthan gum 0.5 g Purified water q.s. Total amount 100 ml (pH 5.5)
- a non-prescription ophthalmic solution of the following formulation was prepared according to a conventional method.
- Naphazoline hydrochloride 0.002 g Allantoin 0.1 g Zinc sulfate 0.1 g Chlorpheniramine maleate 0.03 g Aminoethylsulfonic acid 0.1 g Boric acid 0.7 g ⁇ -Aminocaproic acid 0.2 g Sodium chloride 0.45 g Chlorobutanol 0.15 g Methyl paraoxybenzoate 0.02 g 1-Menthol 0.03 g dl-Camphor 0.003 g Eucalyptus oil 0.0009 g Geraniol 0.0009 g Macrogol 4000 0.3 g Xanthan gum 0.2 g Purified water q.s. Total amount 100 ml (pH 5.8)
- a non-prescription ophthalmic solution of the following formulation was prepared according to a conventional method.
- an ophthalmic solution comprising xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content, can be provided.
- the ophthalmic solution of the present invention provides an excellent feel during use due to a viscous feel free of stickiness and a refreshing feel.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present invention relates to an ophthalmic solution comprising xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content.
- Many of general ophthalmic solutions contain terpenoids such as menthol, camphor, borneol and the like as algefacients in order to provide a cool sensation and a refreshing feel upon instillation. While plastic containers are generally used for such ophthalmic solutions, the terpenoid content is known to decrease when a drug containing terpenoid is filled and preserved in a plastic container. To solve this problem,
JP-A-2000-273061 JP-A-2002-003364 - Lacrimal fluid is known to have pseudoplasticity. That is, the viscosity of lacrimal fluid decreases when a force is applied by blinking, and increases when the force is not applied. Therefore, lacrimal fluid has unique property in that it has low viscosity and becomes thin during blinking to facilitate blinking, but it becomes highly viscose before and after blinking to cover the eye surface for protection. As a polymer compound showing such pseudoplasticity, xanthan gum is known.
- As an ophthalmic composition containing xanthan gum, the following have been reported. For example, an ophthalmic composition containing echothiopate iodide and xanthan gum is disclosed, and xanthan gum has been reported to enhance the treatment effect of echothiopate iodide (
US Patent No. 4136177 ). In addition, an ophthalmic composition containing xanthan gum and a carbonic anhydrase inhibitor has been disclosed, where xanthan gum is used to improve ophthalmic bioavailability of the carbonic anhydrase inhibitor (JP-T-2001-508035 JP-T-2002-501017 JP-T-2002-506461 JP-T-2002-501533 JP-T-2002-521332 JP-T-2002-521333 JP-T-2001-516713 JP-T-2002-510654 US Patent No. 6623751 reports in connection with skin patches that can be adapted to the shape of around the eye, forehead, nose, the mouth and the like, a patch containing a hydrophilic gelling system in an aqueous phase. Example 3 ofUS Patent No. 6623751 reports a patch containing xanthan gum and menthol. - However, there has been no report on an ophthalmic solution comprising xanthan gum and terpenoid. Moreover, suppression of decrease in the terpenoid content by xanthan gum in an ophthalmic solution has not been reported.
- An object of the present invention is to provide an ophthalmic solution comprising terpenoid, which shows a suppressed decrease in the terpenoid content. Another object of the present invention is to provide a method for suppressing a decrease in the content of terpenoid in an ophthalmic solution comprising terpenoid.
- The present inventors have conducted intensive studies in an attempt to achieve the aforementioned objects and found that addition of xanthan gum to an ophthalmic solution comprising terpenoid can suppress a decrease in the terpenoid content. The present inventors conducted further studies based on this finding and accomplished the present invention.
- Accordingly, the present invention relates to
- (1) an ophthalmic solution comprising xanthan gum and terpenoid;
- (2) the ophthalmic solution of (1) above, wherein the terpenoid is menthol and/or camphor;
- (3) the ophthalmic solution of (1) or (2) above, wherein the concentration of the xanthan gum is 0.2-0.7 w/v%;
- (4) the ophthalmic solution of any one of (1) to (3) above, wherein the concentration of the terpenoid is 0.002-0.05 w/v%;
- (5) the ophthalmic solution of any one of (1) to (4) above, wherein a container used therefor is a plastic container; and
- (6) a method for suppressing a decrease in the content of terpenoid, which comprises adding xanthan gum to an ophthalmic solution comprising terpenoid.
- According to the present invention, an ophthalmic solution showing a suppressed decrease in the terpenoid content can be provided by adding xanthan gum. Moreover, a method for suppressing decrease in the content of terpenoid in an ophthalmic solution, which comprises adding xanthan gum to an ophthalmic solution containing terpenoid, can be provided. Furthermore, the ophthalmic solution of the present invention provides an excellent feel during use due to a viscous feel free of stickiness and a refreshing feel it provides in combination, since it comprises xanthan gum and terpenoid.
- The present invention is described in more detail in the following.
- The ophthalmic solution of the present invention encompasses aqueous formulations that can be administered to the eye, for example, aqueous ophthalmic solutions and aqueous ophthalmic suspensions.
- While a container to be used for the ophthalmic solution of the present invention is not particularly limited insofar as it is usable for the aqueous formulations, plastic containers are preferable. Examples of the materials of the plastic containers include polyethylene terephthalate, polyethylene, polypropylene and the like. Polyethylene terephthalate is particularly preferable.
- Xanthan gum to be used for the ophthalmic solution of the present invention generally has an average molecular weight of 100000-50000000, preferably 200000-20000000, and particularly preferably 1000000-10000000. As the xanthan gum, ECHO GUM series such as ECHO GUM T, ECHO GUM F and the like that are commercially available from DAINIPPON SUMITOMO PHARMACEUTICAL CO., LTD.; SAN-ACE series such as SAN-ACE NXG-S and the like commercially available from San-Ei Gen F.F.I. Inc.; KELTROL series such as KELTROL CG, KELTROL CG-T and the like commercially available from Sansho Co., Ltd.; and the like are used, with preference given to ECHO GUM T and KELTROL CG-T.
- The xanthan gum in the ophthalmic solution of the present invention has a concentration of generally 0.01-1.5 w/v%, preferably 0.1-1 w/v%, more preferably 0.15-1 w/v%, particularly preferably 0.2-0.7 w/v%, and especially preferably 0.2-0.6 w/v%, in view of suppression of decrease in the terpenoid content. An ophthalmic solution having a xanthan gum concentration of 1.5 w/v% or lower can be produced easily because it has suitable viscosity and allows filtration sterilization under general conditions.
- Examples of terpenoids to be used for the ophthalmic solution of the present invention include menthols (1-menthol, d-menthol, dl-menthol and the like); camphors (1-camphor, d-camphor, dl-camphor and the like); monoterpenes (borneol, geraniol, cineol, anethole, limonene, eugenol and like); sesquiterpenes (farnesol, nerolidol and like); diterpenes (phytol, cembrene and like); etc., with preference given to menthol and camphor. These are used in combination of one or more kinds thereof.
- The terpenoid concentration of the ophthalmic solution of the present invention upon preparation is generally 0.0002-0.2 w/v%, preferably 0.001-0.1 w/v%, and particularly preferably 0.002-0.05 w/v%.
- For suppression of decrease in the terpenoid content, the weight ratio of terpenoid to xanthan gum in the ophthalmic solution of the present invention upon preparation is preferably 1:1000-1:1 and more preferably 1:100-1:10 when the terpenoid concentration is 0.001-0.1 w/v%. When the terpenoid concentration is 0.002-0.05 w/v%, the weight ratio is preferably 1:350-1:4 and more preferably 1:100-1:10.
- The ophthalmic solution of the present invention can contain various additives as appropriate, such as buffer, isotonicity agent, preservative, solubilizing agent, stabilizer, chelating agent, thickener, pH adjusting agent and the like.
- As the buffer, for example, boric acid or a salt thereof (sodium borate, etc.), citric acid or a salt thereof (sodium citrate, etc.), tartaric acid or a salt thereof (sodium tartrate, etc.), gluconic acid or a salt thereof (sodium gluconate, etc.), acetic acid or a salt thereof (sodium acetate, etc.), phosphoric acid or a salt thereof (sodium hydrogenphosphate, sodium dihydrogenphosphate, etc.), various amino acids such as glutamic acid, ε-aminocaproic acid and the like and tris buffer, etc. can be mentioned. They are used in a combination of one or more kinds thereof.
- As the isotonicity agent, for example, sorbitol, glucose, mannitol, glycerol, propylene glycol, sodium chloride, potassium chloride and the like can be mentioned.
- As the preservative, for example, paraoxybenzoates, benzalkonium chloride, benzethonium chloride, benzyl alcohol, sorbic acid or a salt thereof, chlorhexidine or a salt thereof, sodium dehydroacetate, cetylpyridinium chloride, alkyldiaminoethylglycine hydrochloride, chlorobutanol and the like can be mentioned. They are used in a combination of one or more kinds thereof.
- As the solubilizing agent, for example, nonionic surfactants such as sorbitan polyoxyethylene fatty acid esters (polysorbate 80 and the like), polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate (polyoxyl stearate 40 and the like) and like, water-soluble polymers such as polyethylene glycol (macrogol 4000 and the like), polyvinylpyrrolidone and the like, propylene glycol, cyclodextrins, and the like can be mentioned.
- As the stabilizer, for example, disodium edetate, thiosodium sulfate, ascorbic acid, cyclodextrins, condensed phosphoric acid or a salt thereof, sulfite, citric acid or a salt thereof, dibutylhydroxytoluene and the like can be mentioned.
- As the chelating agent, for example, sodium edetate, sodium citrate, condensed phosphoric acid or a salt thereof (condensed sodium phosphate etc.) and the like can be mentioned.
- As the thickener, for example, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, hyaluronic acid and the like can be mentioned.
- As the pH adjusting agent, for example, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, boric acid or a salt thereof (sodium borate), hydrochloric acid, citric acid or a salt thereof (sodium citrate, sodium dihydrogen citrate etc.), phosphoric acid or a salt thereof (sodium dihydrogen phosphate, potassium dihydrogen phosphate etc.), acetic acid or a salt thereof (sodium acetate, ammonium acetate etc.), tartaric acid or a salt thereof (sodium tartrate etc.) and the like can be mentioned.
- The ophthalmic solution of the present invention is prepared to have pH 3-10 and preferably pH 5-8.
- The ophthalmic solution of the present invention may contain, insofar as the objects of the invention are not impaired, one or more kinds of medicinal components selected from anti-inflammatory agents (allantoin, pranoprofen and the like), decongestants (naphazoline hydrochloride and the like), ocular muscle modulators (neostigmine methylsulfate and the like), astringent agents (zinc sulfate and the like), antihistamine agents (chlorpheniramine maleate and the like), antiallergic agents (sodium cromoglycate and the like), vitamins (panthenol and the like), amino acids, and the like.
- As the amino acid, for example, glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, serine, threonine, tyrosine, asparagine, glutamine, lysin, arginine, tryptophan, histidine, cysteine, methionine, aspartic acid, glutamic acid, aminoethylsulfonic acid, and a pharmacologically acceptable salt thereof can be mentioned. As the salt, for example, sodium salt, potassium salt, calcium salt and magnesium salt can be mentioned. These are used in a combination of one or more kinds thereof.
- Administration period of the ophthalmic solution of the present invention is not limited. The ophthalmic solution can be suitably administered to an administration subject based on the clinically employed amount as a standard. The blending ratio of the ophthalmic solution of the present invention and the above-mentioned medicinal components can be suitably selected in consideration of the administration subject, target disease, symptom, combination, and the like. For example, when the administration subject is a human, the above-mentioned medicinal components may be used in a proportion of 0.0006-5 w/v% relative to the ophthalmic solution of the present invention.
- The ophthalmic solution of the present invention can be used as both ethical drugs and non-prescription drugs. In addition, it can also be used as an ophthalmic solution for contact lenses or a contact lens solution used when wearing contact lenses. The ophthalmic solution of the present invention can also be used as an ophthalmic solution for the prophylaxis or improvement of eye fatigue, dryness of eye, blurred vision, ocular itching, conjunctival hyperemia, uncomfortableness by wearing contact lenses, and the like. Moreover, the ophthalmic solution of the present invention can be used as an artificial lacrimal fluid to supplement lacrimal fluid (dryness of the eye) and the like.
- For example, when the ophthalmic solution of the present invention is used for an adult, it is preferably administered in an amount of 2-3 drops per installation and 5 or 6 times per day, as an ophthalmic solution containing terpenoid in a proportion of preferably 0.001-0.1 w/v% and particularly preferably 0.002-0.05 w/v%.
- The ophthalmic solution of the present invention exhibits a viscous feel free of stickiness because it contains xanthan gum, which shows pseudoplasticity. Moreover, the ophthalmic solution of the present invention also provides a cool sensation and refreshing feel because it contains terpenoid as an algefacient.
- The present invention provides a method for suppressing decrease in the terpenoid content, which comprises adding xanthan gum to an ophthalmic solution containing terpenoid.
- While the present invention is described in detail in the following by referring to Examples and Experimental Examples, which are not to be construed as limitative.
- Sodium chloride was dissolved in purified water at ambient temperature. While mildly stirring the aqueous solution in a homomixer (T.K. Robomix, Tokushu Kika Kogyo Co., Ltd.), xanthan gum (ECHO GUM T: registered trade mark, DAINIPPON SUMITOMO PHARMACEUTICAL CO., LTD.) was gradually added and the mixture was stirred at 15,000 rpm for one hour. 1-Menthol (The Japanese Pharmacopoeia Fourteenth Edition) or dl-camphor (The Japanese Pharmacopoeia Fourteenth Edition) was added to this aqueous solution at room temperature and the mixture was stirred at 8,000 rpm for 10 min to allow dissolution. The aqueous solution was filtered through a membrane filter (0.45 µm pore diameter, Pressure Filter, manufactured by Millipore) to give ophthalmic solutions of Examples 1 to 4. In addition, ophthalmic solutions of Comparative Examples 1 and 2 were obtained by an operation in the same manner except addition of xanthan gum.
(Table 1) Components added (g/100 mL) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Comp. Ex. 1 Comp. Ex. 2 Xanthan gum 0.2 0.5 0.7 0.5 - - Sodium chloride 0.9 0.9 0.9 0.9 0.9 0.9 1-Menthol 0.01 0.01 0.01 - 0.01 - dl-Camphor - - - 0.01 - 0.01 Purified water e.q. e.q. e.q. e.q. e.q. e.q. - The ophthalmic solutions of Examples 1 to 4 and Comparative Examples 1 and 2 were each filled in a 15 mL polyethylene terephthalate eyedrop container and preserved at 60°C for 2 days. The 1-menthol and dl-camphor contents of each sample were measured before and after preservation. The quantification method of 1-menthol and dl-camphor is as follows.
- A sample (2 mL) was precisely measured, and precisely 2 mL of chloroform was added thereto. The mixture was then vigorously shaken, the chloroform layer was separated and used as a sample solution. Separately, 0.02 g of 1-menthol standard product was precisely measured, and chloroform was added thereto to precisely 20 mL. This solution (2 mL) was precisely measured off, chloroform was added thereto to precisely 20 mL, and the solution was used as an 1-menthol standard solution. Moreover, 0.02 g of dl-camphor standard product was precisely measured, and chloroform was added thereto to precisely 20 mL. This solution (2 mL) was precisely measured off, chloroform was added thereto to precisely 20 mL, and the solution was used as a dl-camphor standard solution. The sample solution and the standard solution (5 µL) were tested by gas chromatography. The contents of 1-menthol and dl-camphor were determined from the peak areas thereof.
AT: Peak area of 1-menthol or dl-camphor in sample solution
AS: Peak area of 1-menthol or dl-camphor in standard solution
Gas chromatography conditions
System: GC-2010 (Shimadzu Corporation)
Detector: Hydrogen flame ionization detector
Column: PEG 20M 20% Gaschrom Q 60/80 mesh 3 mm ×2 m glass column (GL Science)
Column temperature: 150°C
Detector temperature: 200°C
Injection temperature: 200°C
Flow rate: arranged to attain 1-menthol retention time of about 8 minutes - As shown in Table 2, the 1-menthol residual ratios increased in Examples 1 to 3 as compared to Comparative Example 1. An 1-menthol content decrease-suppressive effect of xanthan gum was observed at respective concentrations of 0.2 to 0.7%. Moreover, the dl-camphor residual rate increased in Example 4 as compared to Comparative Example 2, and a dl-camphor content decrease-suppressive effect of xanthan gum was observed.
(Table 2) Terpenoid content decrease-suppressive effect of xanthan gum in polyethylene terephthalate eyedrop container (60°C, 2 day preservation) Xanthan gum content (%) 1-Menthol residual rate (%) dl-Camphor residual rate (%) Example 1 0.2 80.4 - Example 2 0.5 86.8 - Example 3 0.7 89.2 - Example 4 0.5 - 95.9 Comparative Example 1 0 74.7 - Comparative Example 2 0 - 80.3 -
(Table 3) Components added (g/100 mL) Ex. 5 Ex. 6 Ex. 7 Comp. Ex. 3 Comp. Ex. 4 Comp. Ex. 5 Xanthan gum 0.5 0.5 0.5 - - - Sodium chloride 0.9 0.9 0.9 0.9 0.9 0.9 1-Menthol 0.002 0.03 0.05 0.002 0.03 0.05 Polysorbate80 - - 0.2 - - 0.2 Purified water q.s. q.s. q.s. q.s. q.s. q.s. - The ophthalmic solutions of Examples 5 to 7 and Comparative Examples 3 to 5 were each filled in a 15 mL polyethylene terephthalate eyedrop container and preserved at 60°C for 2 days. The 1-menthol content of each sample before and after the preservation was measured in the same manner as in Experimental Example 1.
- As shown in Table 4, the 1-menthol residual rate increased in Examples 5 to 7 as compared to Comparative Examples 3 to 5. An 1-menthol content decrease-suppressive effect of xanthan gum was observed at any concentration of 1-menthol.
(Table 4) Menthol content decrease-suppressive effect of xanthan gum (60°C, 2 day preservation) Xanthan gum content (%) 1-Menthol content (%) 1-Menthol residual rate (%) Example 5 0.5 0.002 90.1 Example 6 0.5 0.03 91.5 Example 7 0.5 0.05 97.7 Comparative Example 3 0 0.002 78.6 Comparative Example 4 0 0.03 71.4 Comparative Example 5 0 0.05 86.2 - The ophthalmic solutions of Example 2 and Comparative Example 1 were filled in a 15 mL polypropylene eyedrop container and a 15 mL polyethylene eyedrop container, respectively, and preserved at 60°C for 6 hr. The 1-menthol content of each sample before and after the preservation was measured in the same manner as in Experimental Example 1.
- As shown in Table 5, the 1-menthol residual rate in Example 2 increased as compared to Comparative Example 1 in both polypropylene eyedrop container and polyethylene eyedrop container. Hence, an 1-menthol content decrease-suppressive effect of xanthan gum was observed.
(Table 5) Menthol content decrease-suppressive effect of xanthan gum in polypropylene or polyethylene eyedrop container (60°C, 6 hr preservation) Xanthan gum content (%) 1-Menthol residual ratio (%) Polypropylene Polyethylene Example 2 0.5 53.0 23.5 Comparative Example 1 0 47.2 15.5 - The ophthalmic solutions of Example 2 and Comparative Example 1 (5 mL each) were filled in 5 mL glass ampoules, a piece of a polyethylene terephthalate container (about 3 g of about 5 mm × 25 mm piece cut out from the body of container) was immersed therein, and the ampoules were preserved at 60°C for 1 day. The 1-menthol content of each sample before and after the preservation was measured in the same manner as in Experimental Example 1. In addition, one free of immersion of a container piece was treated in the same manner.
- As shown in Table 6, the 1-menthol residual rate increased in Example 2 as compared to Comparative Example 1. From this result, it is considered that xanthan gum suppressed adsorption of menthol to the container as one mechanism of the content decrease-suppressive effect.
(Table 6) Menthol content decrease-suppressive effect of xanthan gum in polyethylene terephthalate container (60°C, 1 day preservation) Xanthan gum content (%) 1-Menthol residual rate (%) No container piece With container piece Example 2 0.5 100.4 96.7 Comparative Example 1 0 100.1 91.1 - Formulation examples of the ophthalmic solution comprising xanthan gum and terpenoid of the present invention are shown below.
- An artificial lacrimal fluid of the following formulation was prepared according to a conventional method.
Potassium 1-aspartate 0.5 g Aminoethylsulfonic acid 0.5 g Sodium chloride 0.5 g Potassium chloride 0.15 g Boric acid 0.3 g Borax q.s. Xanthan gum 0.5 g Benzalkonium chloride 0.005 g 1-Menthol 0.005 g Purified water q.s. Total amount 100 ml (pH 7.2) - A contact lens ophthalmic solution of the following formulation was prepared according to a conventional method.
Sodium chloride 0.55 g Potassium chloride 0.15 g Glucose 0.005 g Boric acid 0.6 g Borax q.s. Xanthan gum 0.3 g Potassium sorbate 0.1 g 1-Menthol 0.01 g Macrogol 4000 0.3 g Sodium edentate 0.1 g Purified water q.s. Total amount 100 ml (pH 6.5) - A contact lens ophthalmic solution of the following formulation was prepared according to a conventional method.
Potassium 1-aspartate 0.1 g Sodium chloride 0.3 g Potassium chloride 0.05 g Glucose 0.005 g Boric acid 1 g Borax q.s. Sodium citrate 0.5 g Chlorobutanol 0.1 g Xanthan gum 0.3 g Sorbic acid 0.1 g 1-Menthol 0.035 g Macrogol 4000 0.3 g Purified water q.s. Total amount 100 ml (pH 6.5) - A non-prescription ophthalmic solution of the following formulation was prepared according to a conventional method.
Neostigmine methylsulfate 0.005 g Panthenol 0.1 g Potassium 1-aspartate 1 g Allantoin 0.1 g Chlorpheniramine maleate 0.03 g Sodium chloride 0.45 g Sodium 1-glutamate 0.2 g Polyoxyethylene hydrogenated castor oil 60 0.3 g 1-Menthol 0.008 g Borneol 0.002 g Hydrochloric acid q.s. Benzalkonium chloride 0.005 g Chlorobutanol 0.2 g Xanthan gum 0.5 g Purified water q.s. Total amount 100 ml (pH 5.5) - A non-prescription ophthalmic solution of the following formulation was prepared according to a conventional method.
Naphazoline hydrochloride 0.002 g Allantoin 0.1 g Zinc sulfate 0.1 g Chlorpheniramine maleate 0.03 g Aminoethylsulfonic acid 0.1 g Boric acid 0.7 g ε-Aminocaproic acid 0.2 g Sodium chloride 0.45 g Chlorobutanol 0.15 g Methyl paraoxybenzoate 0.02 g 1-Menthol 0.03 g dl-Camphor 0.003 g Eucalyptus oil 0.0009 g Geraniol 0.0009 g Macrogol 4000 0.3 g Xanthan gum 0.2 g Purified water q.s. Total amount 100 ml (pH 5.8) - A non-prescription ophthalmic solution of the following formulation was prepared according to a conventional method.
Sodium cromoglycate 1 g Chlorpheniramine maleate 0.015 g Pranoprofen 0.05 g Boric acid 1.8 g Borax 0.35 g Sodium edetate 0.01 g 1-Menthol 0.005 g Polysorbate 80 0.2 g Xanthan gum 0.3 g Purified water q.s. Total amount 100 ml (pH 7) - According to the present invention, an ophthalmic solution comprising xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content, can be provided. The ophthalmic solution of the present invention provides an excellent feel during use due to a viscous feel free of stickiness and a refreshing feel.
- While some of the embodiments of the present invention have been described in detail in the above, those of ordinary skill in the art can enter various modifications and changes to the particular embodiments shown without substantially departing from the novel teaching and advantages of the present invention. Such modifications and changes are encompassed in the spirit and scope of the present invention as set forth in the appended claims.
- This application is based on application No. 2005-201871 filed in Japan, the contents of which are incorporated hereinto by reference.
Claims (6)
- An ophthalmic solution comprising xanthan gum and terpenoid.
- The ophthalmic solution of claim 1, wherein the terpenoid is menthol and/or camphor.
- The ophthalmic solution of claim 1 or 2, wherein the concentration of the xanthan gum is 0.2-0.7 w/v%.
- The ophthalmic solution of any one of claims 1 to 3, wherein the concentration of the terpenoid is 0.002-0.05 w/v%.
- The ophthalmic solution of any one of claims 1 to 4, wherein a container used therefor is a plastic container.
- A method for suppressing a decrease in the content of terpenoid, which comprises adding xanthan gum to an ophthalmic solution comprising terpenoid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06781152T PL1911447T3 (en) | 2005-07-11 | 2006-07-11 | Eye drop preparation comprising xanthan gum and terpenoid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005201871 | 2005-07-11 | ||
PCT/JP2006/314129 WO2007007894A1 (en) | 2005-07-11 | 2006-07-11 | Eye drop preparation comprising xanthan gum and terpenoid |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1911447A1 true EP1911447A1 (en) | 2008-04-16 |
EP1911447A4 EP1911447A4 (en) | 2009-03-25 |
EP1911447B1 EP1911447B1 (en) | 2009-12-23 |
Family
ID=37637263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06781152A Not-in-force EP1911447B1 (en) | 2005-07-11 | 2006-07-11 | Eye drop preparation comprising xanthan gum and terpenoid |
Country Status (9)
Country | Link |
---|---|
US (1) | US7998942B2 (en) |
EP (1) | EP1911447B1 (en) |
JP (1) | JP4966854B2 (en) |
KR (1) | KR101322527B1 (en) |
CN (1) | CN101212960B (en) |
DE (1) | DE602006011330D1 (en) |
ES (1) | ES2337501T3 (en) |
PL (1) | PL1911447T3 (en) |
WO (1) | WO2007007894A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102196A3 (en) * | 2009-03-05 | 2011-01-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
WO2011018800A3 (en) * | 2009-08-13 | 2011-07-21 | Fdc Limited | In-situ gel forming solution for ocular drug delivery |
WO2013056327A1 (en) * | 2011-10-17 | 2013-04-25 | Fbm Indústria Farmacêutica Ltda. | Cleaning solution for contact lenses |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2014333A1 (en) | 2007-07-12 | 2009-01-14 | Hakiman Shargh Research Company | Use of cooling agents for treatment or prevention of lacrimation or eye burning |
CN102085395A (en) * | 2009-12-02 | 2011-06-08 | 日本乐敦制药株式会社 | Ophthalmological composition for silicone hydrogel contact lens |
WO2015029924A1 (en) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | Ophthalmological composition |
CN103805069B (en) * | 2014-01-27 | 2016-03-02 | 欧普康视科技股份有限公司 | A kind of contact lens polishing fluid and preparation method thereof |
US20180098937A1 (en) * | 2016-10-12 | 2018-04-12 | Ps Therapies Ltd | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
JP2018111691A (en) * | 2017-01-11 | 2018-07-19 | 千寿製薬株式会社 | Aqueous ophthalmic composition and method for suppressing reduction in amount of compound |
WO2021107033A1 (en) * | 2019-11-29 | 2021-06-03 | 千寿製薬株式会社 | Pharmaceutical composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0392845A2 (en) * | 1989-04-14 | 1990-10-17 | Minnesota Mining And Manufacturing Company | Solid gel external drug delivery system |
US5888515A (en) * | 1997-12-11 | 1999-03-30 | Albros, L.P. | Rhus dermatitis treatment composition and method |
EP1022017A2 (en) * | 1999-01-20 | 2000-07-26 | Stada Arzneimittel Ag | Cosmetic or pharmaceutical compositions for topical administration with improved stability |
US20030059446A1 (en) * | 2001-09-18 | 2003-03-27 | Kulkarni Arun B. | Physically stable sprayable gel composition |
WO2003080011A1 (en) * | 2002-03-22 | 2003-10-02 | Unilever Plc | Stabilization of terpenoids in cosmetic compositions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
JP3570444B2 (en) * | 1995-06-05 | 2004-09-29 | ライオン株式会社 | Mouthwash |
EP0917873B1 (en) * | 1996-09-26 | 2006-08-16 | Rohto Pharmaceutical Co., Ltd. | Eyedrops |
FR2754712B1 (en) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | OPHTHALMIC COMPOSITIONS |
US20020094981A1 (en) * | 1997-05-30 | 2002-07-18 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
WO1999000133A1 (en) | 1997-06-26 | 1999-01-07 | Merck & Co., Inc. | Method for optimizing retinal and optic nerve health |
US6277365B1 (en) * | 1997-09-18 | 2001-08-21 | Bausch & Lomb Incorporated | Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
US6156785A (en) * | 1998-01-23 | 2000-12-05 | Merck Sharp & Dohme B.V. | Method for increasing oxygen tension in the optic nerve and retina |
US6174524B1 (en) * | 1999-03-26 | 2001-01-16 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
CA2337399A1 (en) | 1998-07-21 | 2000-02-03 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
CA2337349A1 (en) | 1998-07-21 | 2000-02-03 | Gerald S. Ponticello | Ophthalmic compositions for treating ocular hypertension |
JP4438908B2 (en) * | 1999-03-19 | 2010-03-24 | 千寿製薬株式会社 | Terpenoid emulsion |
JP4748289B2 (en) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | Eye drops, ophthalmic composition, and adsorption suppression method |
EP1312356B1 (en) * | 2000-08-25 | 2012-10-17 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations |
JP2003128583A (en) | 2001-08-15 | 2003-05-08 | Rohto Pharmaceut Co Ltd | Refreshing composition |
WO2006035969A1 (en) | 2004-09-28 | 2006-04-06 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition containing xanthan gum and amino acid |
-
2006
- 2006-07-11 EP EP06781152A patent/EP1911447B1/en not_active Not-in-force
- 2006-07-11 DE DE602006011330T patent/DE602006011330D1/en active Active
- 2006-07-11 US US11/988,489 patent/US7998942B2/en not_active Expired - Fee Related
- 2006-07-11 WO PCT/JP2006/314129 patent/WO2007007894A1/en active Application Filing
- 2006-07-11 PL PL06781152T patent/PL1911447T3/en unknown
- 2006-07-11 JP JP2007524724A patent/JP4966854B2/en active Active
- 2006-07-11 KR KR1020087000902A patent/KR101322527B1/en not_active IP Right Cessation
- 2006-07-11 CN CN2006800239849A patent/CN101212960B/en not_active Expired - Fee Related
- 2006-07-11 ES ES06781152T patent/ES2337501T3/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0392845A2 (en) * | 1989-04-14 | 1990-10-17 | Minnesota Mining And Manufacturing Company | Solid gel external drug delivery system |
US5888515A (en) * | 1997-12-11 | 1999-03-30 | Albros, L.P. | Rhus dermatitis treatment composition and method |
EP1022017A2 (en) * | 1999-01-20 | 2000-07-26 | Stada Arzneimittel Ag | Cosmetic or pharmaceutical compositions for topical administration with improved stability |
US20030059446A1 (en) * | 2001-09-18 | 2003-03-27 | Kulkarni Arun B. | Physically stable sprayable gel composition |
WO2003080011A1 (en) * | 2002-03-22 | 2003-10-02 | Unilever Plc | Stabilization of terpenoids in cosmetic compositions |
Non-Patent Citations (1)
Title |
---|
See also references of WO2007007894A1 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102196A3 (en) * | 2009-03-05 | 2011-01-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
WO2011018800A3 (en) * | 2009-08-13 | 2011-07-21 | Fdc Limited | In-situ gel forming solution for ocular drug delivery |
WO2013056327A1 (en) * | 2011-10-17 | 2013-04-25 | Fbm Indústria Farmacêutica Ltda. | Cleaning solution for contact lenses |
Also Published As
Publication number | Publication date |
---|---|
DE602006011330D1 (en) | 2010-02-04 |
JPWO2007007894A1 (en) | 2009-01-29 |
PL1911447T3 (en) | 2010-03-31 |
US7998942B2 (en) | 2011-08-16 |
EP1911447A4 (en) | 2009-03-25 |
EP1911447B1 (en) | 2009-12-23 |
WO2007007894A1 (en) | 2007-01-18 |
JP4966854B2 (en) | 2012-07-04 |
CN101212960A (en) | 2008-07-02 |
KR101322527B1 (en) | 2013-10-25 |
CN101212960B (en) | 2011-04-13 |
ES2337501T3 (en) | 2010-04-26 |
KR20080041621A (en) | 2008-05-13 |
US20090054531A1 (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1911447B1 (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
JP3090125B2 (en) | Ophthalmic composition for soft contact lens, method for enhancing wettability of soft contact lens, and method for suppressing adsorption of terpenoid | |
AU2007338210B2 (en) | Gel useful for the delivery of ophthalmic drugs | |
EP2002841A1 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
JP2003183157A (en) | Ophthalmologic composition | |
JP2002003364A (en) | Eye drop, ophthalmic composition and method for adsorption control | |
JP6452283B2 (en) | Eye foreign substance feeling improving agent | |
JP7458159B2 (en) | Ophthalmic Composition | |
JP2006022087A (en) | Refreshing composition for ophthalmology | |
JP2005187407A (en) | Ophthalmic composition for allergic eye disease | |
JP2001261578A (en) | Ophthalmic composition | |
JP2004002358A (en) | Ophthalmic composition | |
JP2019065008A (en) | Ophthalmic composition, method for producing the same, and method for suppressing adsorption | |
JP2003073303A (en) | Method for maintaining refreshing activity of eye drops | |
NZ201111A (en) | Pharmaceutical compositions containing guanethidine and a beta2-receptor | |
JP2005104970A (en) | Composition for contact lens | |
EP2977044B1 (en) | Two-layer separation-type eye drop containing squalane | |
JP2003055201A (en) | Solubilized composition containing vitamin a compounds and method for stabilizing vitamin a compounds | |
EP2419081B1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
JP2018203723A (en) | Contact lens eye drop for friction reduction, method of using the same, and method of reducing friction of contact lens when worn | |
JP2009079032A (en) | Composition for ophthalmic use and method for stabilizing diphenhydramine | |
JP2018052996A (en) | Eye drops for alleviating foreign substance sensation | |
JP2016040319A (en) | Refreshing composition for ophthalmology | |
JP2023166315A (en) | Ophthalmic composition | |
JP2021105065A (en) | Eye drops for alleviating foreign body sensation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090225 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602006011330 Country of ref document: DE Date of ref document: 20100204 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2337501 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100323 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100423 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100423 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100711 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100624 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20120711 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20120705 Year of fee payment: 7 Ref country code: TR Payment date: 20120705 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20120814 Year of fee payment: 7 Ref country code: IT Payment date: 20120725 Year of fee payment: 7 Ref country code: ES Payment date: 20120710 Year of fee payment: 7 Ref country code: DE Payment date: 20120927 Year of fee payment: 7 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130711 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006011330 Country of ref document: DE Effective date: 20140201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130731 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130711 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130712 Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130711 |